Vaximm will start a clinical trial on the first ever investigational oral cancer vaccine, the company announced today.
The study will enrol 45 pancreatic cancer patients who will receive several doses of the VXM01 vaccine, which is designed to stimulate the immune system to destroy the blood vessels essential for tumour growth.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Patients will treated at the Heidelberg University Hospital in Germany and results of the study will be announced in the first half of 2013.
The vaccine is the first cancer vaccine being investigated, which is given orally and which acts in the gut to induce an anti-tumour response of the immune system.
Principal investigator Dr Hubertus Schmitz-Winnenthal said, "I am delighted about the transition of this therapeutic cancer vaccine into clinical evaluation. In animal experiments conducted by us and others, VXM01 showed an impressive anti-tumour activity.
"We are very keen on exploring the safety and potential efficacy of this vaccine in inoperable pancreatic cancer patients, as a first step in the clinical evaluation of VXM01."
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataCaption: Oral vaccines are currently used to prevent diseases such as polio.
